Orexigen’s Contrave COR-I Trial Results Published Online in Journal Lancet

Orexigen’s Contrave COR-I published in Lancet
Orexigen® Therapeutics, Inc. announced that from its COR-I of Contrave® were published today in the Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. show that patients taking Contrave were two to three times more likely to lose …
Read more on News-Medical-Net

Leaders criticized in Army suicides
WASHINGTON – After nine years of war, the Army attracts recruits ready for combat but inclined toward risky personal behavior – a volatile mix that led to more deaths from suicide, drug overdoses and drinking and driving than from warfare, an Army review concludes.
Read more on The Oshkosh Northwestern

Tags: , , , ,

Leave a Reply

Spam Protection by WP-SpamFree

Translator
English flagItalian flagKorean flagChinese (Simplified) flagChinese (Traditional) flagPortuguese flagGerman flagFrench flagSpanish flagJapanese flagArabic flag
Russian flagGreek flagDutch flagBulgarian flagCzech flagCroatian flagDanish flagFinnish flagHindi flagPolish flagRomanian flag
Swedish flagNorwegian flagCatalan flagFilipino flagHebrew flagIndonesian flagLatvian flagLithuanian flagSerbian flagSlovak flagSlovenian flag
Ukrainian flagVietnamese flagAlbanian flagEstonian flagGalician flagMaltese flagThai flagTurkish flagHungarian flagBelarus flagIrish flag
Icelandic flagMacedonian flagMalay flagPersian flag